Stem cells represent a potential cellular resource in the development of regenerative medicine approaches to the treatment of pathologies in which specific cells are degenerated or damaged by genetic abnormality, disease, or injury. Securing sufficient supplies of cells suited to the demands of cell transplantation, however, remains challenging, and the establishment of safe and efficient cell banking procedures is an important goal. Cryopreservation allows the storage of stem cells for prolonged time periods while maintaining them in adequate condition for use in clinical settings. Conventional cryopreservation systems include slow-freezing and vitrification both have advantages and disadvantages in terms of cell viability and/or scalability. In the present study, we developed an advanced slow-freezing technique using a programmed freezer with a magnetic field called Cells Alive System (CAS) and examined its effectiveness on human induced pluripotent stem cell-derived neural stem/progenitor cells (hiPSC-NS/PCs). This system significantly increased cell viability after thawing and had less impact on cellular proliferation and differentiation. We further found that frozen-thawed hiPSC-NS/PCs were comparable with non-frozen ones at the transcriptome level. Given these findings, we suggest that the CAS is useful for hiPSC-NS/PCs banking for clinical uses involving neural disorders and may open new avenues for future regenerative medicine.
Safe and efficient method for cryopreservation of human induced pluripotent stem cell-derived neural stem and progenitor cells by a programmed freezer with a magnetic field 
Introduction
A growing body of evidence indicates that stem cells may serve as a useful source for regenerative medicine applications targeting certain refractory diseases. Neural stem and progenitor cells (NS/PCs) derived from human fetus and/or embryonic stem cells (ESCs) represent one potential source of transplantation approach for neurodegenerative diseases and neurotraumatic injuries, such as brain infarction and spinal cord injury (SCI). While NS/PCs can be incorporated into host tissues and restore nervous system functionality Okano et al., 2013) , the harvesting of such cells from a human fetus confronts legal and ethical challenges in many countries including Japan. Since the development of a new technique for establishing human induced pluripotent stem cells (hiPSCs) from somatic tissues (Takahashi et al., 2007) , hiPSCs have become an attractive alternative cell source due to their ease of generation and comparative lack of ethical baggage.
In Japan, there is an ongoing project to establish a hiPSCs bank to provide cells for use in allogeneic transplantation (Nakatsuji et al., 2008; Okano and Yamanaka, 2014; Okita et al., 2011) . We have previously reported the effectiveness of transplanting hiPSCderived NS/PCs (hiPSC-NS/PCs) for SCI in rodents and non-human primates (Imaizumi et al., 2012; Kobayashi et al., 2012; Nori et al., 2011) . Because it takes about six months to establish hiPSC-NS/PCs derived from an SCI patient's autologous somatic cells (Okada et al., 2008) , at present it is impossible to perform auto-graft of iPSC-NS/PCs within the optimal therapeutic time window for sub-acute SCI (from 2 to 4 weeks after injury) (Nishimura et al., 2014; and Yamanaka, 2014) . To extend our results into potential clinical applications, therapeutic strategies will heavily rely on allogeneic transplantation of hiPSC-NS/PCs. We note here that hiPSC-NS/PCs may need to be stored properly to achieve favorable outcomes after transplantation. Cryopreservation makes it possible to store cells for prolonged time periods adequate for the clinical setting, although hiPSC-NS/PCs should be cryopreserved with high survival rates and minimal impact on cellular properties such as proliferation and developmental potency after freezing and thawing. Cryopreserved cells intended for clinical use must further be validated at given time points to avoid significant adverse outcomes such as failure to engraft into recipient tissue. However, few studies to date have evaluated NS/PC properties before and after freezing and thawing (Hancock et al., 2000; Ma et al., 2010; Milosevic et al., 2005; Paynter, 2008; Tan et al., 2007) .
Currently preferred procedures for preparing cryopreserved cells are classified into two general types: slow-freezing and vitrification. The slow-freezing procedure has the beneficial aspect of enabling the preparation of large quantities of vials at one time, while the vitrification method is superior in terms of cell survival. Recently, the Cells Alive System (CAS) (ABI corporation Ltd., Abiko, Japan) was developed as a novel freezing technology and it has been used in the cryopreservation of various kinds of cells, including murine osteoblasts, rat bone tissue fragments, rat mesenchymal stem cells (MSCs), human periodontal ligament cells, and human ES cells (Abedini et al., 2011; Kaku et al., 2010 Kaku et al., , 2014 Kaku et al., , 2015 Kojima et al., 2013 Kojima et al., , 2015 Koseki et al., 2013; Lin et al., 2013) and proven to be a more effective method for cell preservation. However, it remains unclear whether this procedure is applicable to the banking of hiPSC-NS/PCs as well.
In this study, we used CAS to cryopreserve hiPSC-NS/PCs and examined the effects of cryopreservation process on hiPSC-NS/PCs. We determined a simple, optimized method designed for clinical use of these cells with improved cell viability without detrimental impact on cell properties using this system.
Materials and methods

Cell culture
The hiPSCs (clone 201B7) were cultured and maintained as described previously Nori et al., 2011; Takahashi et al., 2007) . To perform neural induction of hiPSCs, we generated embryoid bodies (EBs) as described previously Nori et al., 2011) . EBs were then enzymatically dissociated into single cells and cultured in suspension in serum-free media hormone mix (MHM) media for 10-14 days to allow the formation of neurospheres . Neurospheres were dissociated into single cells and then cultured in the same manner for passage. The diameters of neurospheres were measured using inverted microscope (IX73, OLYMPUS Corporation, Tokyo, Japan). To evaluate cell viability, cells were enzymatically dissociated immediately after thawing in a water bath at 37 • C for 2 min and viable cells were counted by trypan blue exclusion test. Five visual fields chosen at random with a 4× objective lens were used to identify the diameter of hiPSC-NS/PCs spheres.
Cell freezing
After partially dissociating the hiPSC-NS/PCs, we counted the viable cells using the trypan blue exclusion test at three or six days after the last passage. A total of 2 or 5 × 10 6 cells were placed as neurospheres in a cryo-tube (Nunc CryoTubes, Thermo Fisher Scientific Inc., MA, USA) with 1 ml cryopreservation solution (STEMCELL-BANKER, ZENOAQ, Fukushima, Japan). For cryopreservation, the • C, for 15 min at −7 • C (supercooling state) and plunged to −70
• C. In this setting, it took about 130 min to became −70
• C.
vials were placed in the CAS programmed freezer containing a magnetic field or a freezing container (Nalgene Mr. Frosty, Thermo Fisher Scientific, MA, USA). The alternating magnetic field with an induced electric field generated by the CAS freezer causes cells and water molecules to vibrate by a non-thermal mechanism and prevents the formation of intracellular ice crystals. As a result, improvement of cell viability would be achieved (Kaku et al., 2010 (Kaku et al., , 2012 . The electric current and frequency were adjusted to change the intensity of the magnetic field in the CAS. The freezing protocol was as follows: 4 • C for 5 min, −7 • C for 15 min, plunged to −70 • C (shown as the gray line in Fig. 1B) ; the electric current of CAS was adjusted as follows: 0.5, 0.4 and 0.3 A. We set the frequency of CAS to 30 Hz. To measure the actual temperature, thermocouple thermometer (testo 735-2, Testo, Kanagawa, Japan) with a sheathtype flexible probe was used in every minute and it was repeated at least three times.
Immunocytochemistry
To perform immunocytochemistry in spheres, we centrifuged the spheres at 1000 rpm for 5 min. Cells were collected using iPGell (GenoStaff, Tokyo, Japan) and postfixed for 1 h in 4% paraformaldehyde (PFA), soaked 4 h in 10% sucrose, 4 h in 20% sucrose, and then overnight in 30% sucrose, following the manufacturer's instructions. We then embedded the spheres in Optimal Cutting Temperature compound (Sakura Finetek Japan Co., Ltd., Tokyo, Japan), and sectioned them at 14 m on a cryostat (Leica CM3050 S, Leica Microsystems, IL, USA). These sections were stained with the following primary antibodies: anti-Ki-67 (rabbit IgG, 1:200, Novocastra, Newcastle upon Tyne, UK), anti-SOX2 (Mouse IgG, 1:500, R&D Systems, MN, USA). Nuclei were stained with Hoechst 33258 (10 g/mL; Sigma Chemical Co., MO, USA). Images were obtained by a confocal laser scanning microscope (LSM780; Carl Zeiss, Jena, Germany). At least seven visual fields chosen at random with a 20× objective lens were used to quantify the Ki-67 positive cells and SOX2 positive cells.
To assay the degree of differentiation by immunostaining, hiPSC-NS/PCs were dissociated into single cells, plated on poly-lornithine/fibronectin-coated cover glasses, and allowed to undergo spontaneous differentiation for 10 days, following a previously reported method (Imaizumi et al., 2012; Okada et al., 2008) . The cells were fixed for 10 min in 8% PFA, then 15 min in 4% PFA. Cells were stained with the following primary antibodies: anti-Hu (human IgG, 1:1000, a gift from Prof. Robert Darnell, The Rockefeller University, New York, NY, USA), anti-glial fibrillary acidic protein (GFAP) (rabbit IgG, 1:200, Dako, CA, USA), anti-2 ,3 -cyclic nucleotide 3 -phosphohydrolase (CNPase) (mouse IgG; 1:1000, Sigma Chemical Co., MO, USA), anti-SOX2 (Mouse IgG, 1:500, R&D Systems, MN, USA), anti-␤-tubulin isotype III (␤III tubulin, Tuj1, Mouse IgG, 1:1000, Sigma Chemical Co., MO, USA). Nuclei were stained with Hoechst 33258 (10 g/mL; Sigma Chemical Co., MO, USA). Images were obtained by a confocal laser scanning microscope (LSM780; Carl Zeiss, Jena, Germany). At least five visual fields chosen at random with a 20× objective lens were used to quantify the Hu-positive cells and SOX2-positive cells.
Microarray analysis
The samples were placed in TRIzol (Invitrogen, CA, USA) and immediately frozen. Total RNA was isolated using Qiagen RNeasy Kit (Qiagen Inc., Hilden, Germany). Microarray analysis was performed using Affymetrix GeneChip technology (Affymetrix Japan, Tokyo, Japan). Total RNA (100 ng) was reverse transcribed, biotin labeled, and hybridized. Hybridization was performed using the Affymetrix GeneChip 3 IVT PLUS Reagent Kit (Affymetrix Japan, Tokyo, Japan) for 16 h at 45 • C. Arrays were scanned using a GeneChip Scanner 3000 (Affymetrix Japan, Tokyo, Japan). Data analysis was performed using Expression Analysis Data Analysis Fundamentals (Affymetrix Japan, Tokyo, Japan). Signal detection, quantification and normalization were performed using the MAS5 algorithm at the default settings, following the manufacturer's instructions. Principal component analysis (PCA) and hierarchical clustering were performed using GeneSpring GX (Agilent Technologies, CA, USA).
Statistical analysis
All data are reported as the mean ± SEM. An unpaired twotailed Student's t test was used to assess the diameter of the neurospheres, the proliferation and differentiation efficacy of hiPSC-NS/PCs between non-frozen and frozen-thawed. One-way ANOVA, followed by the Scheffe's multiple comparison test was used for the survival. In each case, *P < 0.05 and **P < 0.01 were considered to be statistically significant.
Results
Validation of CAS for cryopreservation of hiPSC-NS/PCs
Since the CAS is reported to be effective for cryopreservation of various cell types, including murine osteoblasts, rat bone Table 1 The intensity of the magnetic field in the CAS. tissue fragments, rat MSCs, human periodontal ligament cells, human erythrocytes, and human ESCs (hESCs) (Abedini et al., 2011; Kaku et al., 2010 Kaku et al., , 2014 Kaku et al., , 2015 Kojima et al., 2013 Kojima et al., , 2015 Koseki et al., 2013; Lin et al., 2013) , we sought to apply this methodology to the cryopreservation of NS/PCs derived from hiPSCs. We first compared the actual temperature of the cryopreservation solution in the CAS with the setting temperature to validate the system. We determined freezing temperature by exothermic reaction. We measured the freezing temperature four times and found out to be −8.5 to −16.0 • C. Fig. 1A shows one of the examples to measure the freezing temperature. To pass more rapidly through the temperature zone at which ice crystals form, we set the sample temperature at −7 • C, which was just above the freezing temperature, known as a "super-cooling state". We maintained this temperature for 15 min to preserve all samples in an individual vial at uniform temperature. The actual temperature is shown in Fig. 1B . The intensity of the magnetic field in the CAS under three conditions we examined in this study is shown in Table 1 .
The CAS improved survival rate of frozen hiPSC-NS/PCs
To examine the impact on cell survival during cryopreservation, we examined the survival rate of hiPSC-NS/PCs immediately after thawing in a water bath at 37 • C for 2 min. Frozen-thawed hiPSC-NS/PCs were partially dissociated and stained by 0.5% trypan blue to estimate the number of dead cells among total cell population. We set up experiments in two conditions for cell preservation: frozen at densities of 2 × 10 6 cells/ml (lower density) and 5 × 10 6 cells/ml (higher density). Cell preservation was performed three or six days after the last passage. For the setting of the CAS, we compared three different settings (0.5, 0.4 and 0.3 A) in the following experiment.
The survival rates of hiPSC-NS/PCs under several conditions are shown in Fig. 2A and B, indicating that the CAS did not have much impact on cell viability compared to classical slow-freezing approach. There were significant differences in cell viability between the CAS at 0.4 A (0.30-0.40 mT) and 0.3 A (0.22-0.29 mT) and the freezing container at all conditions examined. The highest cell viability was achieved when hiPSC-NS/PCs were frozen at 2 × 10 6 cells/ml six days after the last passage using the CAS at 0.4 A (0.30-0.40 mT). Thus, we decided to use this setting for further experiments, and describe the characterization of cryopreserved hiPSC-NS/PCs in the following section.
We next assessed the diameter of the non-frozen neurospheres and frozen-thawed neurospheres derived from hiPSC-NS/PCs, which were frozen at the density of 2 × 10 6 cells/ml three and six days after the last passage using the CAS at 0.4 A (0.30-0.40 mT) or the freezing container. These results indicated a significant size difference in neurospheres frozen using these two methods, as shown in Fig. 2C and D.
We speculated that the reduction of the diameter after thawing was due to cell death, caused by the mechanical stress of freezing and thawing. The difference of the diameter after thawing between the CAS and freezing container was also due to cell death and mechanical stress. Freezing by CAS may thus confer less stress to cells than freezing by conventional container. Cells were frozen at 3 days after the last passage (Day 3) (A) and 6 days after the last passage (Day 6) (B). The number of frozen cells was 2 × 10 6 cells/ml and 5 × 10 6 cells/ml. The best viability was 66.6% when hiPSC-NS/PCs were frozen at Day 6 and at the density of 2 × 10 6 cells/ml using the CAS programmed freezer with a 0.30-0.40 mT magnetic field (0.4 A). The CAS programmed freezer increased the cell survival after freezing and thawing, especially with a 0.30-0.40 mT magnetic field (0.4 A). There were significant differences between 0.22 and 0.29 mT (0.3 A), 0.30-0.40 mT (0.4 A) and the freezing container in any timing and density. (C, D) The diameter of non-frozen and frozen-thawed neurospheres. We assessed the diameter of the non-frozen neurospheres and frozen-thawed neurospheres including hiPSC-NS/PCs, which were frozen at the density of 2 × 10 6 cells/ml at Day 3 (C) and Day 6 (D) using the CAS programmed freezer with a 0.30-0.40 mT magnetic field (0.4 A) or the freezing container. There was a significant difference in the diameter of frozen-thawed neurospheres between the CAS programmed freezer and freezing container at both Day 3 and Day 6. Fig. 3 . Immunostaining of the non-frozen and frozen-thawed neurospheres, which were frozen at 3 days and 6 days after the last passage. (A, B) Immunostaining for Ki-67 and SOX2. (C, D) Quantitative analysis of Ki-67 and SOX2-positive cells in the non-frozen and frozen-thawed neurospheres which were frozen at 3 days and 6 days after the last passage. There was no significant difference in proliferation ability between non-frozen and frozen-thawed cells. Scale bar = 100 m.
Proliferative property of hiPSC-NS/PCs were unchanged using the CAS
Based on these findings, we assessed the proliferation ability of these frozen-thawed hiPSC-NS/PCs, which were cryopreserved at lower density using the CAS at 0.4 A (0.30-0.40 mT) 3 or 6 days after the last passage and compared with non-frozen cells. We assessed the proliferation ability of non-frozen and frozen-thawed neurospheres derived from hiPSC-NS/PCs by immunostaining for Ki-67 and SOX2 (Fig. 3A and B ). There were no significant differences in proliferation ability between the non-frozen and frozen-thawed hiPSC-NS/PCs under the specific conditions described above ( Fig. 3C  and D) .
Differentiation ability was maintained in cryopreserved hiPSC-NS/PCs
To assess the differentiation ability of non-frozen and frozenthawed hiPSC-NS/PCs, we induced differentiation of hiPSC-NS/PCs for 10 days in vitro and, subsequently assessed them for differentiation ability to examine the expression of lineage specific markers; Hu for neurons, GFAP for astrocytes, CNPase for oligodendrocytes, and SOX2 for undifferentiated neural progenitor cells. We prepared frozen hiPSC-NS/PCs, which had been frozen at lower density three or six days after the last passage. As shown in Fig. 4A and B, these hiPSC-NS/PCs had a trend to predominantly differentiate into Hu-positive neurons and they could produce less glial cells including GFAP-positive astrocytes and CNPase-positive oligodendrocytes, which are known differentiation properties of hiPSC-NS/PCs in vitro . Unexpectedly, we noticed that significant number of Hu-positive cells also expressed SOX2, indicating that majority of neurons generated in our experimental paradigm were immature and hiPSC-NS/PCs probably need more time to differentiate into mature neurons. However, at least, we could confirm that freezing-thaw process did not affect initial neuronal differentiation program, which are most important in terms of clinical application of hiPSC-NS/PCs to neurological diseases. To confirm the differentiation ability of hiPSC-NS/PCs into neurons, we also used ␤III tubulin marker and found␤III tubulin-positive neurons in all conditions (Fig. 4C ). There were no significant differences in the percentages of Hu and SOX2-positive cells between the non-frozen and the frozen-thawed cells under the specific condition as described above ( Fig. 4D and E) .
Transcriptome analysis of non-frozen and frozen hiPSC-NS/PCs
Given the similarities between non-frozen and frozenthawed hiPSC-NS/PCs by the CAS in terms of proliferation and differentiation kinetics, we sought to perform detailed characterization of hiPSC-NS/PCs by transcriptome analysis. We performed microarray analysis using a series of hiPSC-NS/PCs, which were non-frozen hiPSC-NS/PCs, frozen-thawed hiPSC-NS/PCs by CAS, frozen-thawed hiPSC-NS/PCs by freezing container, and hiPS cells, as shown in Fig. 5 . The samples of hiPSC-NS/PCs were harvested at three and six days after the last passage. Frozen-thawed samples were obtained from two separate vials stored under the same condition. We performed principal component analysis (PCA) with three principal components (PC1, 2 and 3) using the microarray data. The contributions of each component were 25.97%, 21.09 and 7.91%, respectively. The samples of hiPS cells, frozen-thawed hiPSC-NS/PCs frozen at 3 and 6 days after the last passage were clearly separated, and samples of frozen-thawed hiPSC-NS/PCs were closely clustered with non-frozen sample in both freezing timing (Fig. 5A) . Two-dimensional hierarchical clustering revealed that the gene expression of frozen-thawed hiPSC-NS/PCs using the CAS and the freezing container formed a distinct cluster in both freezing timing. Furthermore, the gene expression profiles of nonfrozen and frozen-thawed hiPSC-NS/PCs were closely clustered in both freezing timing (Fig. 5B) . These findings suggest that freezing and thawing by CAS or freezing container does not significantly affect the cells' gene expression profiles.
Discussion
In this study, we validated the procedures for cryopreservation of hiPSC-NS/PCs to apply them for future clinical application to the CNS disorders and traumas. Although we demonstrated the effectiveness of the CAS for clinical research settings, a series of studies has examined the impact of cryopreservation steps on various kinds of NS/PCs, including NS/PCs derived from mouse ESCs (Hancock et al., 2000) , mouse fetal forebrain (Milosevic et al., 2005) and human fetal CNS (Vescovi et al., 1999) . This series of studies showed cell viability, cell fate determination and proliferation after the freezing-thawing process, but to date there have been no studies in which freezing protocols are directly compared in detail, nor are there any guidelines governing the preservation of NS/PCs for clinical use, probably due to a lack of generalized procedures of cryopreservation.
The two most commonly used methods of cryopreservation are vitrification and slow-freezing. Vitrification freezes cells quickly by immersing into liquid nitrogen directly. Although ice crystal formation is completely prevented, vitrification requires a high concentration of cryoprotective agents, which is toxic to most cells (Fahy et al., 2004a,b; Fowler and Toner, 2005) . In the actual clinical setting, the cells for transplantation should be intensively washed to remove the toxic reagent. Moreover, vitrification also requires additional special skills and is not suitable for large amounts of cells (Fahy et al., 2004a,b; Fowler and Toner, 2005; Li et al., 2010; Reubinoff et al., 2001; Richards et al., 2004; Vajta and Nagy, 2006; Zhou et al., 2004) . Therefore, this procedure is not commonly used for clinical studies. In contrast, slow-freezing method had an advantage in terms of handling and less-toxic reagent required for the cryopreservation. Usually the cells are gradually frozen in a deep freezer or programmed freezer with low concentration of cryoprotective agents, which might not cause serious toxic and osmotic damage (Mazur, 1990) . However, a large amount of ice crystals formed inside the cells injure the cellular membrane. This is explained by an insufficient volume of cryoprotective agents to prevent ice crystal formation. If the penetration is too slow, cells are exposed to the cryoprotective agents for a long time. As a result, cells would be damaged (Al-Hasani et al., 2007; Balaban et al., 2008; Fowler and Toner, 2005; Kuwayama et al., 2005; Paynter, 2008; Pedro et al., 2005; Rama Raju et al., 2005) . This technique does not require special skills and has allowed to freeze large amounts of cells, but after thawing recovery is low compared with vitrification (Imaizumi et al., 2014) . Although these two procedures have both merits and demerits, slow-freezing would be more advanced side for cell-banking because of the convenience and allowance of freezing large amount of cells.
To improve cell survival in slow-freezing, at first, we focused on the cryopreservation solution, STEM CELL-BANKER, which is chemically-defined and xeno-free, making it suitable for clinical application (Holm et al., 2010) . It contains 10% DMSO, glucose and high polymer described in the Japanese Pharmacopeia (JP) as a second cryoprotective agent plus NaCl, KCl, Na 2 HPO 4 , HK 2 PO 4 , NaHCO 3 as pH adjusters for maintenance of the cell function (Holm et al., 2010) .
We next focused on the freezing method, temperature, the number of frozen cells and the timing of cryopreservation (it means the diameter of neurospheres). The survival and quality of the cryopreserved materials are also issues in the food industry, and a new cryopreservation technology called "Cells Alive System" (CAS) that uses a newly programmed freezer system and a magnetic field, has been developed. When frozen foods are thawed, damaged cells lose intracellular water and many compounds affecting product flavor. Because cells contain clusters of water molecules, when cells freeze, clusters may grow inside cells and damage the cell membrane. However, alternating magnetic fields with an induced electric field generated by the CAS freezer causes cells and water molecules to vibrate by a non-thermal mechanism. These vibrations are amplified in concert with mechanical and thermal vibrations (CAS vibration), which prevents the formation of intracellular ice crystals (Kaku et al., 2010 (Kaku et al., , 2012 . This effect has been verified by scanning electron microscope (SEM) images which show the miniaturization of intracellular ice crystals by use of CAS freezer (Owada, 2011) . Further, Iwasaka et al. (2011) reported that fine ice crystals, which strongly scatter the irradiating light, increased in the early phase of the super-cooling state when a pulsed train magnetic field was applied. Previous reports showed the successful cryopreservation and transplantation of periodontal ligament cells using the CAS (Abedini et al., 2011; Kaku et al., 2010 Kaku et al., , 2015 . Additionally, murine osteoblasts, rat bones, rat MSCs and human embryonic stem cells were cryopreserved by the CAS programmed freezer (Kaku et al., 2014; Kojima et al., 2013 Kojima et al., , 2015 Koseki et al., 2013; Lin et al., 2013) . They reported CAS improved cell survival and cryopreserved cells had as same function as nonfrozen cells.
We found that the best viability was 66.6% when the hiPSC-NS/PCs were frozen at 2 × 10 6 cells/ml at 6 days after the last passage using CAS under 0.4 A (0.30-0.40 mT) condition by slowfreezing, whereas it was 34.0% using freezing container. Cell viability was superior when frozen at a density of 2 × 10 6 cells/ml than 5 × 10 6 cells/ml. We thought that the temperature did not become uniform when the cell density was too high. Some neurospheres could not be sufficiently cooled, and were damaged as a result. We assessed a fewer number of hiPSC-NS/PCs, the survival was extremely low (data not shown). There may thus be an optimal cell density during freezing.
It is also better to be frozen at six days after the last passage than 3 days after the last passage. The diameter of neurospheres at three and six days was 54.7 ± 1.1 and 80.2 ± 2.9 m, respectively. We thought that penetration of the cryopreservation solution to neurospheres was insufficient when the diameter of neurospheres was too large. As a result, the cells would die. When we assessed larger neurospheres, survival was extremely low (data not shown). There should thus be an optimal diameter of the neurospheres in the freezing process. A previous study by Ma et al. (2010) reported that the sphere diameters might affect the survival rate, supporting our present findings.
One might have interests on the mechanistic insight regulating improved survival rate achieved in the CAS system. Since we found the significant difference in the diameter of neurospheres after thawing between using CAS and freezing container, we speculated the difference was due to cell death caused by the mechanical stress of freezing and thawing. As described above, CAS generates the alternating magnetic fields, which causes cells and water molecules to vibrate. This CAS vibration prevents the formation of intracellular ice crystals and damaging the cell membrane. In our microarray analysis, there are only a few cell-death associated genes changed between the cells frozen using CAS and ones using freezing container and therefore, molecular mechanism regulating the cell survival by the CAS cannot be simply explained by transcriptome analysis. The detailed molecular mechanism underlying the CAS system need to be unraveled in the future study.
In the present study, we showed an improvement in cell viability using CAS under specific conditions. There was significant difference in the cell viability among the different CAS conditions (0.4 A and 0.3 A) and the freezing container. We determined 0.4 A (0.30-0.40 mT) condition of the CAS would be optimal for cryopreservation of hiPSC-NS/PCs.
In terms of proliferation and differentiation ability, CAS had no significant effect on cell proliferation or differentiation ability, consistent with previous reports (Abedini et al., 2011; Hancock et al., 2000; Kaku et al., 2010 Kaku et al., , 2014 Kaku et al., , 2015 Kojima et al., 2013 Kojima et al., , 2015 Koseki et al., 2013; Lin et al., 2013; Ma et al., 2010; Milosevic et al., 2005; Paynter, 2008; Tan et al., 2007) . Moreover, PCA and hierarchical clustering indicated that the gene expression profiles of cells frozen and thawed cells using CAS or freezing container were similar to those of non-frozen cells.
Conclusions
CAS cryopreservation dramatically improved cell survival immediately after thawing and did not significantly affect proliferation, differentiation or gene expression. We plan to cryopreserve hiPSC-NS/PCs in STEM CELL-BANKER by slow-freezing method using the CAS protocol described above and transplant cells immediately after thawing to SCI patients in future clinical studies.
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